UNSPSC 51162340: Chlorpheniramine/methscopolamine/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE500. This VA Drug Class (RE500) classifies this compound as belonging to the group COLD REMEDIES, COMBINATIONS.

UNSPSC 51162340 Chlorpheniramine/methscopolamine/phenylephrine is a Commodity code that, based on recent state and local solicitation activity, encompasses pharmaceuticals and over-the-counter health products procured by county health departments and cooperative purchasing alliances for community health and emergency response initiatives. State and local governments buying under this code are acquiring specific pharmaceutical products—including naloxone, generic multi-source drugs, and OTC medications—through both direct county procurement and statewide cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and authorized distribution channels.

Solicitation activity shows a mix of county-level health departments and state-administered cooperative purchasing alliances. Seminole County, Florida (health department) issued an IFB on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, using electronic bidding through the county's e-Procurement Portal with a response deadline of July 26, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. Geographic activity spans Florida and the Upper Midwest (Minnesota, Oregon), with procurement routed through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and subject to cGMP certification, FDA compliance, and Drug Supply Chain Security Act requirements.